A phase I study of anti‐GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage‐colony stimulating factor in patients with metastatic melanoma Academic Article Article uri icon

Overview

MeSH Major

  • Critical Care
  • Internal Medicine
  • Internship and Residency

abstract

  • Combination therapy with R24 and M-CSF resulted in both clinical and biologic effects that warrant further investigation of this combination.

publication date

  • January 1995

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19950501)75:9<2251::AID-CNCR2820750910>3.0.CO;2-F

PubMed ID

  • 7536122

Additional Document Info

start page

  • 2251

end page

  • 7

volume

  • 75

number

  • 9